Clinical trial
Study of PI-88 in Patients With Advanced Melanoma
NCT00068172 · Cellxpert Biotechnology Corp., Industry · Completed
Key facts
| NCT number | NCT00068172 |
|---|---|
| Title | Study of PI-88 in Patients With Advanced Melanoma |
| Official title | A Phase I/II Study of PI-88 in Advanced Malignancies (Phase I), and in Advanced Melanoma (Phase II) |
| Lead sponsor | Cellxpert Biotechnology Corp., Industry |
| Collaborators | Medigen Biotechnology Corporation Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | PI-88 |
| Enrollment | 88 |
| Start date | Jul 1, 2001 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Sep 10, 2003 |
| Last update posted | Jun 27, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: